一个随机的第一阶段研究调查肠道微生物组变化与moxifloxacin和口服万科米辛:Clostridioides difficile风险的影响
Hossaena Ayele1, Jinhee Jo2, Khurshida Begum2
1Center for Infectious Diseases, UTHealth Houston School of Public Health, University of Texas Health Science Center at Houston.
The Journal of infectious diseases
|October 13, 2025
概括
莫西弗洛克萨极小地破坏了肠道微生物群,但改变了胆酸,可能短暂增加了Clostridioides difficile感染的风险. 范科米辛导致了更深刻,更持久的肠道变化.
科学领域:
- 微生物组研究的研究.
- 代谢学 代谢学 代谢学
- 抗生素对肠道微生物群的影响.
背景情况:
- 流行性Clostridioides difficile ribotype 027 (RT 027) 菌株表现出增强的毒性,包括快速发芽和诺基诺耐药性.
- 虽然诺基诺与RT 027流行病有关,但莫西素对C. difficile感染 (CDI) 造成的特定风险需要进一步调查.
- 这项研究调查了莫西弗洛克萨辛与万科米辛对健康个体肠道微生物组和代谢组的影响.
研究的目的:
- 评估莫西弗洛克萨和万科米对健康志愿者的微生物分类学概况的影响.
- 为了评估由莫克西和万科米辛诱导的代谢变化,特别是胆酸概况.
- 了解这些抗生素可能影响C. difficile感染风险的潜在机制.
主要方法:
- 一个第一阶段,非盲目的随机临床试验,涉及18-40岁的健康志愿者.
- 参与者接受了moxifloxacin或vancomycin口服治疗10天.
- 便样本使用16S rRNA测序进行分析,以测量甲氧经济学和液体染色学-双重质谱测量胆汁酸代谢物.
主要成果:
- 莫西弗洛克萨造成了有限的微生物破坏,克洛斯特里迪亚类物种的短暂变化和从0日到7日的二次胆酸减少.
- 范科米辛诱导了更实质性的微生物组变化,包括蛋白质细菌的增加,Clostridiales丰度的减少和二次胆汁酸的长期减少.
- 肠道干扰的持续时间和程度在两种抗生素之间有显著差异.
结论:
- 莫西弗洛克萨辛的使用与明显的,尽管寿命较短的微生物组和代谢学转变有关,这可能会增加CDI风险.
- 这些发现表明,存在潜在的脆弱性窗口,可以解释基诺和RT 027菌株与快速发芽的关联.
- 莫西弗洛克萨辛和万科米辛对肠道环境的影响差异突出了CDI发展的不同风险.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
423
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
423
Antimicrobial Effectiveness
904
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
904
Drugs for Treatment of Diarrhea-Predominant IBS
631
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
631
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
617
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
617
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488


